{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:24:14Z","timestamp":1775183054888,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease of the CNS caused by the human polyomavirus 2 (JCV). PML predominantly occurs in immunocompromised patients. To date, no specific antiviral treatment exists, leaving only restoration of the immune system as possible treatment. In 2019, the monoclonal antibody pembrolizumab was reported as a potential treatment option in PML in a case series. Following case reports could not thoroughly confirm a positive outcome. Pembrolizumab targets the inhibitory programmed cell death protein 1 (PD-1) receptor on lymphocytes and is associated with beneficial expansion of pre-existing virus-specific T cells. Here we describe a patient with PML who benefited from combined treatment with intravenous immunoglobulins, maraviroc, and pembrolizumab.<\/jats:p>","DOI":"10.1007\/s13365-022-01059-2","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T14:34:32Z","timestamp":1648046072000},"page":"335-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7345-7701","authenticated-orcid":false,"given":"Fabian","family":"Boesl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Allers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane","family":"Herm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Scheider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiana","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"1059_CR1","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597\u20131605. https:\/\/doi.org\/10.1056\/NEJMoa1815039","journal-title":"N Engl J Med"},{"key":"1059_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/jha2.56","volume":"1","author":"I Dufour","year":"2020","unstructured":"Dufour I, Duprez T, Wertz M, Saussoy P, Ackermans N, El Sankari S, van Pesch V, van den Neste E (2020) Improvement in progressive multifocal leukoencephalopathy after pembrolizumab\u2010induced immune reconstruction inflammatory syndrome in a patient with follicular lymphoma. eJHaem 1:585\u2013588. https:\/\/doi.org\/10.1002\/jha2.56","journal-title":"eJHaem"},{"key":"1059_CR3","doi-asserted-by":"publisher","unstructured":"Hodecker SC, St\u00fcrner KH, Becker V, Elias-Hamp B, Holst B, Friese MA, Heesen C (2017) Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol Neuroimmunol Neuroinflamm 4. https:\/\/doi.org\/10.1212\/NXI.0000000000000325","DOI":"10.1212\/NXI.0000000000000325"},{"key":"1059_CR4","doi-asserted-by":"publisher","unstructured":"Holmes A, Wellings T, Walsh O, Rowlings P (2020) Progressive multifocal leukoencephalopathy associated with a lymphoproliferative disorder treated with pembrolizumab. J Neurovirol. https:\/\/doi.org\/10.1007\/s13365-020-00899-0","DOI":"10.1007\/s13365-020-00899-0"},{"key":"1059_CR5","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1941874420902872","volume":"10","author":"RK Kapadia","year":"2020","unstructured":"Kapadia RK, Ney D (2020) Stabilization of progressive multifocal leukoencephalopathy after pembrolizumab treatment. Neurohospitalist 10:238\u2013239. https:\/\/doi.org\/10.1177\/1941874420902872","journal-title":"Neurohospitalist"},{"key":"1059_CR6","doi-asserted-by":"publisher","unstructured":"Mahler C, Andrews M, Henson SM, Gnanapavan S (2020) Sequential interleukin 2 and pembrolizumab use in progressive multifocal leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 7. https:\/\/doi.org\/10.1212\/NXI.0000000000000756","DOI":"10.1212\/NXI.0000000000000756"},{"key":"1059_CR7","doi-asserted-by":"publisher","first-page":"175628642199368","DOI":"10.1177\/1756286421993684","volume":"14","author":"N M\u00f6hn","year":"2021","unstructured":"M\u00f6hn N, Wattjes MP, Adams O, Nay S, Tkachenko D, Salge F, Heine J, Pars K, H\u00f6glinger G, Respondek G, Stangel M, Skripuletz T, Jacobs R, S\u00fchs K-W (2021) PD-1-inhibitor pembrolizumab for treatment of progressive multifocal leukoencephalopathy. Ther Adv Neurol Disord 14:175628642199368. https:\/\/doi.org\/10.1177\/1756286421993684","journal-title":"Ther Adv Neurol Disord"},{"key":"1059_CR8","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","volume":"1","author":"EC Neil","year":"2017","unstructured":"Neil EC, DeAngelis LM (2017) Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 1:2041\u20132045. https:\/\/doi.org\/10.1182\/bloodadvances.2017008201","journal-title":"Blood Adv"},{"key":"1059_CR9","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMc1817193","volume":"380","author":"S Rauer","year":"2019","unstructured":"Rauer S, Marks R, Urbach H, Warnatz K, Nath A, Holland S, Weiller C, Grimbacher B (2019) Treatment of progressive multifocal leukoencephalopathy with pembrolizumab. N Engl J Med 380:1676\u20131677. https:\/\/doi.org\/10.1056\/NEJMc1817193","journal-title":"N Engl J Med"},{"key":"1059_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10072-020-04582-4","volume":"42","author":"J St\u00f6gbauer","year":"2021","unstructured":"St\u00f6gbauer J, Schulz-Schaeffer W, M\u00fchl-Benninghaus R, Lochner P (2021) Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report. Neurol Sci 42:357\u2013359. https:\/\/doi.org\/10.1007\/s10072-020-04582-4","journal-title":"Neurol Sci"},{"key":"1059_CR11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/QAI.0b013e31825a313c","volume":"60","author":"CS Tan","year":"2012","unstructured":"Tan CS, Bord E, Broge TA, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D (2012) Koralnik IJ (2012) Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr\u00a0(1999) 60:244\u2013248. https:\/\/doi.org\/10.1097\/QAI.0b013e31825a313c","journal-title":"J Acquir Immune Defic Syndr\u00a0(1999)"},{"key":"1059_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp-2015-311411","volume":"87","author":"MP Wattjes","year":"2016","unstructured":"Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, de Vos M, Richert ND, Uitdehaag BMJ, Barkhof F, Killestein J (2016) MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 87:879\u2013884. https:\/\/doi.org\/10.1136\/jnnp-2015-311411","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-022-01059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-022-01059-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-022-01059-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T16:57:41Z","timestamp":1654880261000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-022-01059-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1007\/s13365-022-01059-2","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,23]]},"assertion":[{"value":"15 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}